We note, that our results and the trial are in stark contrast to observational studies associating higher G-CSF plasma levels78,79 and rhG-CSF treatment among cancer patients with a poor prognosis80,81, possibly explained by the inability to distinguish cause and effect. This evidence concerns the gene CSF3 and cancer.